Paul A. Friedman is Director at MADRIGAL PHARMACEUTICALS, INC. (MDGL). They have made 28 open-market trades across 4 companies since 2006, most recently 2026-01-09.
CIK 0001236927
10 open-market purchases totalling $1.4M since 2006, against 18 sales. Across 10 scored buys the stock is down 0.6% at ninety days, and 1.7 points behind the S&P over the same stretch.
10 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 10% | 0% | 20% |
| Avg Move | -21.4% | -5.8% | -0.6% |
| Alpha | -17.3% | -4.2% | -1.7% |
| Scored | 10 | 10 | 10 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| MDGL | SELL | 2026-01-09 | 2026-01-13 | $522.39 | $12.8M | +1.3% | -3.8% | +6.7% |
| MDGL | SELL · 10b5-1 | 2026-01-09 | 2026-01-13 | $551.24 | $154K | +1.3% | -3.8% | +6.7% |
| MDGL | SELL · 10b5-1 | 2025-12-10 | 2025-12-12 | $552.18 | $26.5M | +5.4% | -10.7% | -23.3% |
| MDGL | SELL · 10b5-1 | 2025-08-13 | 2025-08-13 | $370.32 | $95.1M | +11.2% | +16.6% | +46.1% |
| MDGL | SELL · 10b5-1 | 2025-08-11 | 2025-08-13 | $355.32 | $30.6M | +11.2% | +16.6% | +46.1% |
| MDGL | SELL · 10b5-1 | 2025-07-18 | 2025-07-22 | $350.03 | $980K | -3.9% | +29.4% | +39.9% |
| MDGL | SELL · 10b5-1 | 2025-07-16 | 2025-07-18 | $353.25 | $19.0M | -13.2% | +17.2% | +32.4% |
| MDGL | SELL · 10b5-1 | 2024-04-08 | 2024-04-10 | $246.19 | $12.9M | -12.9% | -16.3% | +19.5% |
| MDGL | SELL · 10b5-1 | 2024-04-03 | 2024-04-05 | $243.97 | $35.2M | -7.1% | -4.2% | +12.5% |
| INCY | SELL | 2019-08-02 | 2019-08-06 | $82.69 | $16.5M | +1.6% | -3.1% | +3.2% |
| MDGL | BUY | 2018-11-20 | 2018-11-23 | $117.88 | $472K | +2.0% | -19.9% | +6.2% |
| MDGL | BUY | 2018-11-19 | 2018-11-19 | $124.00 | $496K | -3.9% | -14.1% | +11.5% |
| MDGL | SELL | 2018-06-11 | 2018-06-12 | $287.46 | $42.3M | +3.6% | +2.5% | -17.5% |
| INCY | SELL | 2017-11-16 | 2017-11-20 | $105.24 | $6.0M | -1.4% | -5.4% | -13.9% |
| INCY | SELL | 2017-03-17 | 2017-03-20 | $148.18 | $6.2M | -7.1% | -16.1% | -17.6% |
| INCY | SELL | 2017-03-16 | 2017-03-20 | $148.72 | $7.4M | -7.1% | -16.1% | -17.6% |
| INCY | SELL | 2017-03-16 | 2017-03-20 | $151.45 | $1.3M | -7.1% | -16.1% | -17.6% |
| INCY | SELL | 2017-02-23 | 2017-02-27 | $120.32 | $6.0M | +3.2% | +4.2% | -2.4% |
| INCY | SELL | 2015-11-17 | 2015-11-19 | $113.83 | $25.6M | -26.4% | -3.0% | -30.1% |
| INCY | SELL | 2015-05-26 | 2015-05-28 | $107.30 | $15.7M | -26.4% | -3.0% | -3.0% |
| INCY | SELL | 2015-05-21 | 2015-05-26 | $108.22 | $11.1M | -26.4% | -3.0% | -3.0% |
| INCY | SELL | 2015-02-13 | 2015-02-18 | $74.32 | $8.9M | -26.4% | -3.0% | -3.0% |
| VSTM | BUY | 2014-12-24 | 2014-12-29 | $8.31 | $25K | -27.9% | -2.7% | -2.7% |
| AUXL | SELL | 2014-12-04 | 2014-12-08 | $33.73 | $1.0M | N/A | N/A | N/A |
| INCY | SELL | 2014-11-06 | 2014-11-07 | $67.87 | $12.6M | -26.4% | -3.0% | -3.0% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.
| AUXL |
| 5,000 |
| — |
| SNTA | 5,681 | — |
| Total | $123.2M |
Shares reported on the most recent Form 4, priced at the 2026-01-13 close. 3 holdings could not be priced and are excluded from the total.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.